Business Wire

The smarter E Europe: Smart Integration Saves Cash and Stabilizes Grids

12.2.2025 18:52:00 EET | Business Wire | Press release

Share

‘Accelerating Integrated Energy Solutions’ - this is the motto of The smarter E Europe 2025, which will take place this year from 7 to 9 May at Messe München.Smart integration is crucial in the evolving energy and mobility sectors. Energy management systems (EMS) for prosumers and businesses have shifted from a nice-to-have to a must-have, making them a key topic at this year’s event.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250212149082/en/

At The smarter E Europe 2025, visitors will find everything for the smart interaction of PV, storage, e-mobility and energy management. (Photo: Solar Promotion GmbH)

GridX, a smart energy company, estimates that the European Home Energy Management System (HEMS) market will expand 11-fold by 2030 across Denmark, Germany, the UK, Italy, the Netherlands, Austria, Sweden, and Spain. This rapid growth reflects increasing demand and evolving regulations.

Regulatory and market requirements

Regulations such as Section 14a of Germany’s Energy Industry Act (EnWG) allow grid operators to control the power output of heat pumps, EV chargers, and battery storage systems. A robust EMS can optimize energy use, reducing reliance on the grid without compromising user comfort.

The challenge of interoperability

Interoperability remains a challenge, with ongoing discussions about standardization. Manufacturer-independent solutions allow greater flexibility for customers. At The smarter E Europe, top industry leaders will address interoperability concerns, emphasizing open standards. In 2018, the OpenEMS Association took a leading role in supporting efforts to create open and manufacturer-independent standards for energy management systems. OpenEMS is not a communication protocol, such as EEBus, but a software platform. The Association counts universities and research institutes, grid operators and industry associations as well as energy management companies among its members.

Focus event hosted by pv magazine and The smarter E Forum

Home energy management is also going to be discussed at the focus event hosted by pv magazine on the second exhibition day, May 8, 2025. Two interactive sessions will shed light on key aspects of quality photovoltaics and storage projects in the small and utility-scale sectors. pv magazine invites interested visitors to ICM – International Congress Center Messe München, room 13, from 1:00pm–5:00pm. It will be held in German. A separate, English-speaking session aimed at an international expert audience will focus on optimizing large-scale storage systems and the quality assurance of planning, design and marketing. Click here to register for the event.

The smarter E Forum will be organizing a dedicated session for prosumer home energy management systems. On Friday, May 9, the key role of HEMS for modern energy management and grid stability will be discussed starting from 1:30pm.

Munich becomes the center of the energy world

In May, at Messe München, innovation will meet practice, and visions will meet concrete solutions. The smarter E Europe shows how the sectors electricity, heat and transportation can be intelligently connected to create a decentralized, digitalized and flexible energy world. From May 7–9, 2025, Messe München is fully booked – the organizers expect more than 3,000 exhibitors and over 110,000 visitors at the exhibition ground covering 206,000 square meters across 19 exhibition halls and the Outdoor Area.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250212149082/en/

Contacts

Press contact:
ressourcenmangel an der Panke GmbH | Schlesische Straße 26/c4 |10997 Berlin
Roberto Freiberger | Tel.: +49 163 8430 943
roberto.freiberger@ressourcenmangel.de

Solar Promotion GmbH | Postfach 100 170 | 75101 Pforzheim
Peggy Härter-Zilay | Tel.: +49 7231 58598-240
zilay@solarpromotion.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye